Clinical trials
Primary Biliary Cholangitis clinical trials
Below are recruiting primary biliary cholangitis clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02137668RecruitingPhase 1
Testing vancomycin for certain pediatric bile duct conditions
This early-phase study tests whether the antibiotic vancomycin can help children with primary sclerosing cholangitis or biliary atresia, and related gut/bile duct problems. It may work by changing gut bacteria, but you would need to avoid certain medicines beforehand.
Sacramento, CaliforniaAges 2 weeks–40 years - NCT05919433Recruiting
Program to find people with primary biliary cholangitis
This trial is testing a “find patients who are missing from care” program for people with primary biliary cholangitis (PBC). It may help connect you to follow-up sooner if you’ve been hard to reach through usual clinic records.
Terrassa, BarcelonaAges 18 years+ - NCT07631442Enrolling by invitation
Digital Health Monitoring for Primary Biliary Cholangitis
This study uses a smartphone app or digital platform to track how you're feeling day-to-day if you have primary biliary cholangitis (PBC), a liver condition where your immune system damages bile ducts. Researchers want to see if this digital monitoring helps them better understand and manage PBC symptoms.
Redwood City, CaliforniaAges 18 years+ - NCT06767605Recruiting
Spanish registry for autoimmune liver diseases
This study collects information from people with autoimmune or cholestatic liver diseases to better understand them and improve care. It does not test a new treatment, but your participation can help future research.
BarcelonaAges 18 years+ - NCT07449793Recruiting
PBC treatment response and long-term health outcomes
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07216235RecruitingPhase 3
Long-term study of saroglitazar for PBC with cirrhosis
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Marietta, GeorgiaAges 18 years+ - NCT07205874Recruiting
Finding PBC early in people with positive AMA
This study looks for early signs of Primary Biliary Cholangitis in people who have a positive AMA blood test but normal liver enzyme levels. It aims to find the disease before it causes symptoms.
MadridAges 18–80 - NCT07161245Recruiting
Fatigue relief study for primary biliary cholangitis
This trial tests a program of exercise, nutrition, and education to help reduce fatigue in people with primary biliary cholangitis. It aims to see if this program can improve energy and quality of life.
Barcelona, BarcelonaAges 18–80 - NCT06365424RecruitingPhase 2/Phase 3
Fenofibrate for Primary Biliary Cholangitis (PBC)
This trial tests whether the drug fenofibrate can help people with primary biliary cholangitis (PBC), a chronic liver disease. It is for patients who have already taken fenofibrate in a previous study and want to continue treatment.
Xi'an, ShaanxiAges 18–75 - NCT05151809Recruiting
Italy-wide database study for adults with primary biliary cholangitis
This study creates a national registry (database) of adults in Italy living with primary biliary cholangitis (PBC). Being included can help doctors better understand the condition and improve future care.
AnconaAges 18 years+ - NCT06755151RecruitingPhase 3
Fenofibrate for primary biliary cholangitis: a real-world study
This study tests fenofibrate, a medicine that may help lower liver enzymes in people with primary biliary cholangitis (PBC). It looks at how well the drug works in everyday medical practice.
Xi'an, ShaanxiAges 18–75 - NCT06755541RecruitingPhase 3
Fenofibrate plus ursodeoxycholic acid for PBC: a real-world study
This trial is testing whether adding fenofibrate to the standard PBC medicine ursodeoxycholic acid helps people with primary biliary cholangitis. It's a real-world study, meaning it looks at how treatments work in everyday practice. You can join only if you have already completed an earlier fenofibrate study.
Xi'an, ShaanxiAges 18–75 - NCT06723275Recruiting
A study on liver transplant for different liver diseases
This trial is testing a new way to see how well patients do after a liver transplant. It includes people with severe cirrhosis, other end-stage liver diseases, or liver cancer.
Ghent, BelgiumAges 18–70 - NCT06675604Recruiting
Liver transplant data collection study
This study collects data from adults listed for liver transplants due to severe liver disease or liver cancer. It aims to improve transplant care by learning from real-world patient information.
ViennaAges 18–70 - NCT03146910Recruiting
Study of primary biliary cholangitis in Switzerland
This study follows adults with primary biliary cholangitis (a long-term liver and bile duct condition). It may help doctors better understand the disease in different people, including those identified by specific blood antibody tests.
Lugano, Canton TicinoAges 18 years+ - NCT06591468Enrolling by invitationPhase 2/Phase 3
Prednisone Plus Ursodeoxycholic Acid for PBC Patients
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
Guangzhou, GuangdongAges 18–75 - NCT06051617RecruitingPhase 3
Seladelpar for liver scarring in primary biliary cholangitis
This trial tests a medicine called seladelpar for people with primary biliary cholangitis (PBC) and cirrhosis, a form of liver scarring. The goal is to see if it can help improve liver health and reduce symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06016842RecruitingPhase 3
Long-term study of elafibranor for primary biliary cholangitis
This trial tests a drug called elafibranor for people with primary biliary cholangitis (PBC), a liver disease. It aims to see if the drug is safe and works well over a long time.
Tucson, ArizonaAges 18 years+ - NCT05751967RecruitingPhase 3
Fenofibrate plus ursodeoxycholic acid for primary biliary cholangitis
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
Lanzhou, GansuAges 18–75 - NCT05749822RecruitingPhase 2/Phase 3
Fenofibrate for primary biliary cholangitis with stable cirrhosis
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
Beijing, Beijing MunicipalityAges 18–75 - NCT03445585Recruiting
Biobank study for primary sclerosing and primary biliary cholangitis
This study collects and stores samples from people with PSC (primary sclerosing cholangitis), PBC (primary biliary cholangitis), and some related liver conditions. Researchers use these samples to better understand these diseases and support future research.
Rochester, MinnesotaAges 18–85 - NCT04181138Recruiting
Study of childhood primary sclerosing cholangitis types
This study follows children and young adults with primary sclerosing cholangitis (PSC) to understand the condition and how it shows up on scans or biopsy. It may help doctors better recognize PSC and choose the best next steps for care.
Los Angeles, CaliforniaAges 2–25 - NCT06905054RecruitingPhase 2
Preventing PSC recurrence after liver transplant
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Scottsdale, ArizonaAges 18–75 - NCT07607353Recruiting
Biodegradable Stents for Primary Sclerosing Cholangitis
This trial tests a new type of stent (a small tube placed in bile ducts) that dissolves on its own over time in patients with primary sclerosing cholangitis (PSC), a rare disease affecting the bile ducts. The goal is to widen narrowed ducts and reduce the need for repeated procedures.
LondonAges 18 years+
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Primary Biliary Cholangitis trials by city
Studies with a site in or near these metro areas.
Primary Biliary Cholangitis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for primary biliary cholangitis?
- Yes. Clin2 currently lists 44 recruiting primary biliary cholangitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary biliary cholangitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary biliary cholangitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.